CYP cynata therapeutics limited

Ann: Strategic Review of Cynata Clinical Development Portfolio, page-5

  1. 9,096 Posts.
    lightbulb Created with Sketch. 7856
    The big news from this is the 300 recruitment rate for Sculptor (so glad new management recognising immediately, the importance of updating the market - that bodes well). That's slightly ahead of my expectations - they do describe accelerated enrolment this year. The rest we knew/expected.

    Whilst the detractors continue to easily bag the stock with our self declared HC Field Marshall out of action with a spot of gout/dysentery/syphilis (who knows?) this should not be overlooked. Even our previous omnipotent and ever optimistic 'leader' had expectations not too far off this:

    "Looks like 220 + now as indicates first week FEB.5 a week and we're done by end 2023."

    Not quite the 340-350 he and other more optimistic holders might have hoped for by now, but if presently 300 and they manage 7 a week for 2023, then they are indeed done on recruitment by 2023, as clearly they have stated in their DFU trial too.

    Expectations are a little hard to grasp at this micro end of the mkt, but against the exhausting gloom and doom detraction of CYP on HC, this news clearly has a few good information points.


    Last edited by bedger: 24/07/23
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
0.000(0.00%)
Mkt cap ! $36.15M
Open High Low Value Volume
16.0¢ 16.0¢ 16.0¢ $1.021K 6.379K

Buyers (Bids)

No. Vol. Price($)
4 77738 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 3400 1
View Market Depth
Last trade - 09.59am 24/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.